ZOLL, WALLABY MEDICAL INK AGREEMENT TO DISTRIBUTE TEMPERATURE MANAGEMENT PRODUCTS IN CHINA

KUALA LUMPUR, Aug 23 (Bernama) -- ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Wallaby Medical Technologies, have announced signing a distribution agreement whereby Wallaby will manage the sales and distribution of ZOLL’s temperature management products in China.

Wallaby Medical Technologies is a medical device company dedicated to treating stroke and cardiac arrest, according to a statement.

“ZOLL is excited to work with Wallaby to further expand the use of the Thermogard XP® in China, allowing more patients to benefit from high-quality targeted temperature management (TTM),” said President, ZOLL Circulation, Neil Johnston.

Meanwhile, Wallaby Medical Chief Executive Officer, Michael Alper said: “Wallaby Medical is dedicated to improving patient care in China through advanced technology, as we pursue our vision of becoming the medical technology company that helps save the most lives affected by stroke and cardiac arrest.”

High-quality TTM relies on speed at induction to achieve a specific temperature and precisely sustain specified temperatures throughout cooling and normothermia phases, which includes a prolonged controlled rewarming phase.

Current cooling devices vary broadly in their ability to deliver speed and precision, but the latitude in dose selection requires high specificity. The goal of a high-quality TTM programme is to improve the potential for good neurological outcome at patient discharge.

Patients discharging neurologically intact often experience easier recoveries and return to a higher and longer-term quality of life, including return to their normal productivity and lives with their loved ones.

The Thermogard XP Intravascular Temperature Management System (IVTM™) offers healthcare providers the precision and speed as characterised in high-quality TTM, resulting in clinically demonstrated improvements in neurological outcomes among survivors of cardiac arrest.

More details at www.zoll.com.

-- BERNAMA